Essential Hypertension: A Metabolic Cause? A Hypothesis

Macieira-Coelho, Eduardo; Garcia-Alves, Mário; Reis-Valle, António
May 1985
Angiology;May1985, Vol. 36 Issue 5, p305
Academic Journal
Forty-five hypertensive patients, 28 women and 17 men, age range between 35 and 65 years (mean 50 years), with blood pressures which current therapy did not succeed to control, were submitted to several examinations in order to identify the cause of their hypertension. We found isolated or combinated abnormal values of aldosterone, renin, calcium and or potassium as the only alterations in 19 patients. We distinguished 4 groups descretionarily classified according to biochemical alterations: renin and aldosterone increase, renin increase, aldosterone increase, calcium and or potassium reduction. The therapy used, intentionally aimed at the correction of the biochemical alterations found. Normal blood pressure was achieved in all patients and simultaneously the biochemical alterations also became normal in patients with isolated hyperreninemia, with combined hyperreninemia and hyperaldosteronemia and in those with hypocalcemia and or hypopotassemia. In patients were only isolated hyperaldosteronemia was found, this condition returned to normal in all except one. We suggest that besides the disturbances in sodium distribution other electrolytes or biochemical alterations may also play an equally important role in regulating, and sustaining essential hypertension.


Related Articles

  • The Resurgence of Aldosterone in Hypertension and Cardiovascular Disease. Freel, E. Marie; Connell, John M. C. // Current Hypertension Reviews;2006, Vol. 2 Issue 1, p21 

    Aldosterone is a key cardiovascular hormone. Recent studies have illustrated its role in cardiac fibrosis and left ventricular hypertrophy as well as in impaired vascular reactivity. Moreover, many of these actions have been shown to be independent of its known effects on blood pressure. In a...

  • Using Plasma Renin (PRA) Testing to Design Follow-Up Drug Treatment Strategies in Hypertensive Patients Already Taking Antirenin System Drugs. Sealey, Jean E.; Laragh, John H. // American Journal of Hypertension;Sep2009, Vol. 22 Issue 9, p950 

    The article presents a commentary on the study about using plasma renin (PRA) testing to design drug treatment strategies in hypertensive patients. According to the authors, the information provided by the test can be used to determine whether the patient is more likely to respond to a...

  • Comparative Effects of Pindolol and Hydrochlorothiazide in Black Hypertensive Patients. Moser, Marvin; Lunn, John // Angiology;Aug1981, Vol. 32 Issue 8, p561 

    This article focuses on the comparative effects of pindolol and hydrochlorothiazide in black hypertensive patients. Most American investigators agree and the Second Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure has again recommended that thiazide...

  • Primary Hyperaldosteronism in the Hypertensive Disease. Fardella, Carlos E.; Carvajal, Cristian A.; Mosso, Lorena M. // Current Hypertension Reviews;2006, Vol. 2 Issue 1, p33 

    Primary aldosteronism (PA) is one of the potentially curable forms of hypertension. The hypertension is secondary to aldosterone action in the kidney, reabsorbing sodium and water that increases the intravascular volume and blood pressure. PA was previously believed to account for less than 1%...

  • Aliskiren. Siragy, Helmy M.; Kar, Santwana; Kirkpatrick, Peter // Nature Reviews Drug Discovery;Oct2007, Vol. 6 Issue 10, p779 

    Aliskiren (Tekturna; Speedel/Novartis) is the first in a new class of drugs that inhibit the protease renin, which has a key role in the regulation of blood pressure. It was approved by the US FDA for the treatment of hypertension in March 2007, and approved in Europe in August 2007 (where it...

  • Clinical Relevance of Plasma Renin Activity in Hypertensive Patients. Mroczek, William J. // Angiology;Apr1978, Vol. 29 Issue 4, p296 

    Focuses on the clinical relevance of plasma renin activity in hypertensive patients. History of the identification of plasma renin; Advances in the development of inhibitors of the renin angiotensin system; New treatment approaches.

  • Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study. de Simone, G.; Olsen, M. H.; Wachtell, K.; Hille, D. A.; Dahlöf, B.; Ibsen, H.; Kjeldsen, S. E.; Lyle, P. A.; Devereux, R. B. // Journal of Human Hypertension;Aug2007, Vol. 21 Issue 8, p625 

    The relation of metabolic syndrome (MetS) with cardiovascular outcome may be less evident when preclinical cardiovascular disease is present. We explored, in a post hoc analysis, whether MetS predicts cardiovascular events in hypertensive patients with electrocardiographic left ventricular...

  • GenSalt: rationale, design, methods and baseline characteristics of study participants.  // Journal of Human Hypertension;Aug2007, Vol. 21 Issue 8, p639 

    Hypertension is a complex disorder influenced by genetic and environmental determinants and their interactions. The objectives of the Genetic Epidemiology Network of Salt Sensitivity (GenSalt) are to localize and identify genes related to blood pressure (BP) responses to dietary sodium and...

  • Rupture of mitral chordae tendineae: adding to the list of hypertension complications. J J-M Juang // Heart;Jun2009, Vol. 95 Issue 12, p976 

    BACKGROUND: Many patients with chordae tendineae rupture (CTR) of the mitral valve have obscure aetiologies. The association between pre-existing hypertension and idiopathic CTR was investigated. METHODS: 494 patients with CTR were identified by searching the computer database. For each patient...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics